EUVIMEDEUVIMED entdecken
LeitlinieSystematische ÜbersichtOpen Access · CC BY 4.0

Cystic Fibrosis Newborn Screening: A Systematic Review-Driven Consensus Guideline from the United States Cystic Fibrosis Foundation

Meghan E McGarry, Karen S Raraigh, Philip Farrell iD, Faith Shropshire, Karey Padding, Cambrey White, M Christine Dorley iD, Steven Hicks iD, Clement L Ren iD, Kathryn Tullis, Debra Freedenberg, Q Eileen Wafford iD und 5 weitere

International Journal of Neonatal Screening · 02.04.2025 · 11 (2) · 24

DOI: 10.3390/ijns11020024 ↗

Kurz gefasst

Leitlinie in der Zeitschrift International Journal of Neonatal Screening, online erschienen am 02.04.2025. Verfasst von Meghan E McGarry und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98105, USA. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Newborn screening for cystic fibrosis (CF) has been universal in the US since 2010; however, there is significant variation among newborn screening algorithms. Systematic reviews were used to develop seven recommendations for newborn screening program practices to improve timeliness, sensitivity, and equity in diagnosing infants with CF: (1) The CF Foundation recommends the use of a floating immunoreactive trypsinogen (IRT) cutoff over a fixed IRT cutoff; (2) The CF Foundation recommends using a very high IRT referral strategy in CF newborn screening programs whose variant panel does not include all CF-causing variants in CFTR2 or does not have a variant panel that achieves at least 95% sensitivity in all ancestral groups within the state; (3) The CF Foundation recommends that CF newborn screening algorithms should not limit CFTR variant detection to the F508del variant or variants included in the American College of Medical Genetics-23 panel; (4) The CF Foundation recommends that CF newborn screening programs screen for all CF-causing CFTR variants in CFTR2; (5) The CF Foundation recommends conducting CFTR variant screening twice weekly or more frequently as resources allow; (6) The CF Foundation recommends the inclusion of a CFTR sequencing tier following IRT and CFTR variant panel testing to improve the specificity and positive predictive value of CF newborn screening; (7) The CF Foundation recommends that both the primary care provider and the CF specialist be notified of abnormal newborn screening results. Through implementation, it is anticipated that these recommendations will result in improved sensitivity, equity, and timeliness of CF newborn screening, leading to improved health outcomes for all individuals diagnosed with CF following newborn screening and a decreased burden on families.

Schlagwörter

Stichwörter der Autor:innen

F508del (p.Phe508del)cystic fibrosiscystic fibrosis transmembrane conductance regulatorgenetic testingimmunoreactive trypsinogennewborn screening

Autor:innen und Institutionen

  • Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98105, USA.
  • Center for Respiratory Biology and Therapeutics, Seattle Children's Research Institute, Seattle, WA 98101, USA.
  • Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
  • Departments of Pediatrics and Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA.
  • Community Representative to the CF Foundation, Bethesda, MD 20814, USA.
  • The Cystic Fibrosis Foundation, Bethesda, MD 20814, USA.

ORCID-Profile: Philip Farrell, M Christine Dorley, Steven Hicks, Clement L Ren, Q Eileen Wafford, Marissa A Taylor, Albert Faro, Marci K Sontag, Susanna A McColley

Förderung

  • NHLBI NIH HHS

Zitieren

APA

McGarry, M. E., Raraigh, K. S., Farrell, P., Shropshire, F., Padding, K., White, C., Dorley, M. C., Hicks, S., Ren, C. L., Tullis, K., Freedenberg, D., Wafford, Q. E., Hempstead, S. E., Taylor, M. A., Faro, A., Sontag, M. K., & McColley, S. A. (2025). Cystic Fibrosis Newborn Screening: A Systematic Review-Driven Consensus Guideline from the United States Cystic Fibrosis Foundation. International Journal of Neonatal Screening, 11(2), 24. https://doi.org/10.3390/ijns11020024

Vancouver

McGarry ME, Raraigh KS, Farrell P, Shropshire F, Padding K, White C, et al. Cystic Fibrosis Newborn Screening: A Systematic Review-Driven Consensus Guideline from the United States Cystic Fibrosis Foundation. International Journal of Neonatal Screening. 2025;11(2):24. doi:10.3390/ijns11020024

BibTeX
@article{McGarry2025,
  author = {McGarry, Meghan E and Raraigh, Karen S and Farrell, Philip and Shropshire, Faith and Padding, Karey and White, Cambrey and Dorley, M Christine and Hicks, Steven and Ren, Clement L and Tullis, Kathryn and Freedenberg, Debra and Wafford, Q Eileen and Hempstead, Sarah E and Taylor, Marissa A and Faro, Albert and Sontag, Marci K and McColley, Susanna A},
  title = {Cystic Fibrosis Newborn Screening: A Systematic Review-Driven Consensus Guideline from the United States Cystic Fibrosis Foundation},
  journal = {International Journal of Neonatal Screening},
  year = {2025},
  volume = {11},
  number = {2},
  pages = {24},
  doi = {10.3390/ijns11020024}
}
Kostenlos starten →